In the global scramble for Covid-19 vaccines, dominated by aggressive nationalist approaches, COVAX has emerged as a promising, nascent, international initiative to develop and equitably distribute Covid-19 vaccines to benefit all countries. In this episode, Steve is joined by Nikolaj Gilbert, President and CEO at PATH; Peggy Hamburg, former Commissioner of the FDA; Kendall Hoyt, Assistant Professor of Medicine at Dartmouth University's Giesel School of Medicine; and Nicole Lurie, Strategic Advisor to the CEO at the Coalition for Epidemic Preparedness Innovations (CEPI) for a discussion about COVAX and its prospects for success. How does it work? What will it cost? What will it take for COVAX to succeed? What role can the United States play in that effort? The panelists discuss these issues and the implications they may have on the trajectory of the pandemic in the United States and around the world. This episode is a condensed version of an August 11 event hosted by the CSIS Commission on Strengthening America’s Health Security: “The Scramble for Vaccines and the COVAX Facility.”